---
schema_version: "secwatch.filing_event.v1"
accession: "0001816590-23-000142"
form_type: "8-K"
ticker: "CMPS"
cik: "0001816590"
company_name: "COMPASS Pathways plc"
filed_at: "2023-12-07T23:59:59+00:00"
generated_at: "2026-06-07T16:21:53.312384+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Compass Pathways appoints Teri Loxam as CFO effective March 1, 2024

## Summary
- Teri Loxam appointed CFO effective March 1, 2024 or filing of 2023 annual report; advisory role until then.
- Compensation: base salary $490,000, target bonus 45%, initial equity awards totaling $1.8M (60% options, 40% RSUs).
- Loxam has >20 years pharma/biotech experience, including CFO at Gameto, Kira, SQZ Biotech; senior IR at Merck, BMS, IMAX.
- Mary-Rose Hughes continues as interim CFO until Effective Date.

## SEC filing metadata
- accession: 0001816590-23-000142
- form_type: 8-K
- ticker: CMPS
- cik: 0001816590
- company_name: COMPASS Pathways plc
- filed_at: 2023-12-07T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1816590/000181659023000142/0001816590-23-000142-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1816590/000181659023000142/cmps-20231205.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001816590-23-000142
- JSON: https://secwatch.observer/filing/0001816590-23-000142.json
- Plain text: https://secwatch.observer/filing/0001816590-23-000142.txt

## Key facts
- Executive change
  Teri Loxam was appointed as Chief Financial Officer at COMPASS Pathways plc.
  - Action: appointed
  - Role: Chief Financial Officer
  source text: appointed Teri Loxam as chief financial officer, principal financial officer and principal accounting officer, effective as of the later of March 1, 2024 or the filing of the Company’s annual report for the period ending December 31, 2023 (the “Effective Date”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1816590/000181659023000142/0001816590-23-000142-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.